Clinical Trials Directory

Trials / Completed

CompletedNCT02214615

Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations

Pilot Study on the Response of Inherited Erythromelalgia Patients With NaV1.7 Mutations to Carbamazepine: Clinical Imaging Study

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
2 (actual)
Sponsor
VA Connecticut Healthcare System · Federal
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

This research study is designed to investigate brain response using fMRI scan, and behavioral responses, to treatment with the drug carbamazepine (CBZ) in patients with the painful sodium channelopathy inherited Erythromelalgia (IEM). This study is designed to identify the central nervous system (CNS) regions that are activated during ongoing or evoked pain attacks, and the altered CNS response to CBZ treatment. This will advance our understanding of how IEM affects the brain. We also hope to validate a pharmacogenic approach to the study of IEM by use of an FDA approved drug. We hope, but cannot be sure, that subjects will directly benefit from this study.

Conditions

Interventions

TypeNameDescription
DRUGCarbamazepineDay 1: Take 200 mg twice a day. Day 2: Take 200 mg twice a day. Day 3: Take 200 mg twice a day. Day 4: Take 200 mg twice a day. Day 5: Take 400 mg twice a day. Day 6: Take 400 mg twice a day. Day 7: Take 400 mg twice a day. Day 8: Take 400 mg twice a day. Day 9: Take 600 mg twice a day. Day 10: Take 600 mg twice a day. Day 11: Take 600 mg twice a day. Day 12: Take 600 mg twice a day. Day 13: Take 800 mg capsules twice a day. Day 14: Take 800 mg twice a day. Day 15: 800 mg twice a day. Day 16: Take 800 mg twice a day. Taper Down (After Visit 4 and 7) If maximal dose of 800 mg/day has been achieved, tapering down will take 9 days Taper down for 600 mg/day will take 6 days, and for 400 mg/day will take 3 days.
DRUGPlacebo

Timeline

Start date
2014-04-01
Primary completion
2016-07-01
Completion
2016-07-01
First posted
2014-08-12
Last updated
2017-06-06
Results posted
2017-06-06

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02214615. Inclusion in this directory is not an endorsement.

Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations (NCT02214615) · Clinical Trials Directory